Published Report - Endocrine Disruption Screening Market Analysis and Opportunities by 2028

The endocrine disruption screening market is projected to reach US$ 153.30 million by 2028 from US$ 126.53 million in 2021; it is expected to grow at a CAGR of 2.8% during 2021 to 2028.

Many chemicals, both natural and man-made, have the potential to imitate or interfere with the endocrine system, which regulates the body's hormones. These chemicals, known as endocrine disruptors, have been linked to developmental, reproductive, brain, immunological, and other disorders. Endocrine disruptors can be present in a variety of ordinary items, such as some plastic bottles and containers, metal food can liners, detergents, flame retardants, food, toys, cosmetics, and pesticides. Pesticides, chemicals, and environmental toxins are screened using a two-tiered method for their potential effect on the oestrogen, androgen, and thyroid hormone systems by the endocrine disruptor screening.

The growth of the endocrine disruption screening market is attributed to the growing research in the biotechnology sector and the rising prevalence of endocrine disorders. However, the high cost of screening technology hampers the market growth.

Published Report - Endocrine Disruption Screening Market: Strategic Insights

Market Insights
Growing Prevalence of Endocrine Disorders Drives Endocrine Disruption Screening Market

Acromegaly (overproduction of growth hormone), obesity, metabolic syndrome, impaired fasting glucose, impaired glucose tolerance, osteoporosis, osteopenia, mild-moderate hypovitaminosis D, erectile dysfunction, dyslipidemia, and thyroiditis are among the endocrine disorders that have a collective prevalence of at least 5% among the adults in the US. Of these conditions, Males have the highest incidence of erectile dysfunction, while females have the highest incidence of osteopenia/osteoporosis. Diabetes mellitus in children and pituitary adenoma are the least common conditions, affecting less than 1% of the US population. Adrenocortical carcinoma, pheochromocytoma, and pituitary adenomas are the conditions with the lowest incidence. Hyperparathyroidism and thyroid disorders are more common in women. Diabetes mellitus is most prevalent among ethnic minorities. Endocrine and metabolic diseases are among the most common modern human ailments, particularly in the US and other countries implementing ample nutrition and screening programs for high-risk individuals. Endocrine disorders such as hyperparathyroidism, primary and secondary hypogonadism, GH deficiency, and hypothyroidism can lead to other disorders, such as metabolic bone disease and diabetes mellitus. Thus, the growing prevalence and incidence of such conditions propel the demand for endocrine disruption screening products.

Assay Type-Based Insights

The endocrine disruption screening market, by assay type, is bifurcated into in-vitro and in-vivo. The in-vitro segment led the market in 2021, contributing to a market share of 64.45%, and is expected to retain its dominance during the forecast period to account for a market share of 65.73% of the overall revenue generated in 2028.

Application-Based Insights

By application, the endocrine disruption screening market is bifurcated into natural materials and synthetic materials. In 2021, the natural materials segment held a larger share of the market. Moreover, the market for the same segment is expected to grow at a faster CAGR of 3.1% during 2021–2028.

Source of Waste-Based Insights

The endocrine disruption screening market, by source of waste, is segmented into incineration and landfill, agricultural runoff, industrial and municipal effluents, pulp mill effluents, consumer products, and others. In 2021, the incineration and landfill segment held the largest share of the market. Moreover, the market for the same segment is expected to grow at the fastest CAGR of 3.5% during 2021–2028.

Method-Based Insights

The endocrine disruption screening market, by method, is segmented into estrogen receptor (ER) transactivation, androgen receptor (AR) transactivation, androgen receptor (AR) modulation, estrogen receptor-alpha (ER) binding, estrogen receptor beta (ER) binding, androgen receptor (AR) binding, steroidogenesis, aromatase assay, and others. In 2021, the estrogen receptor (ER) transactivation segment held the largest share of the market. Moreover, the market for the same segment is expected to grow at the fastest CAGR of 3.7% from 2021 to 2028.

End-User-Based Insights

The endocrine disruption screening market, based on end use, is segmented into pharmaceutical and biopharmaceutical companies, cosmetics and household product companies, food industry, and chemical industry. In 2021, the pharmaceutical and biopharmaceutical companies segment held the largest share of the market. Moreover, the market for the same segment is expected to grow at the fastest CAGR of 3.3% during 2021–2028.

Product launches and approvals are commonly adopted strategies by companies to expand their global footprints and product portfolios. Moreover, the endocrine disruption screening market players focus on the partnership strategy to enlarge their clientele, which, in turn, permits them to maintain their brand name across the world.

Endocrine Disruption Screening

Published Report - Endocrine Disruption Screening Market Players Density: Understanding Its Impact on Business Dynamics

The Published Report - Endocrine Disruption Screening Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

The report segments endocrine disruption screening market as follows

Endocrine Disruption Screening Market – by Assay Type

• In-Vitro
• In-Vivo

Endocrine Disruption Screening Market – by Application

• Natural Materials
• Synthetic Materials

Endocrine Disruption Screening Market – by Sources of Waste

• Incineration and Landfill
• Agricultural Runoff
• Industrial and Municipal Effluents
• Pulp Mill Effluents
• Consumer Products
• Others

Endocrine Disruption Screening Market – by Method

• Estrogen Receptor (ER) Transactivation
• Androgen Receptor (AR) Transactivation
• Androgen Receptor (AR) Modulation
• Estrogen Receptor-Alpha (ER-alpha) Binding
• Estrogen Receptor Beta (ER-beta) Binding
• Androgen Receptor (AR) Binding
• Steroidogenesis
• Aromatase Assay
• Others

Endocrine Disruption Screening Market – by End User

• Pharmaceutical and Biopharmaceutical Companies
• Chemical Industry
• Food Industry
• Cosmetics and Household Product Companies 

Endocrine Disruption Screening Market – by Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Middle East and Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of Middle East and Africa
• South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America

Company Profiles

• CREATIVE BIOARRAY
• XENOMETRIX AG
• CHARLES RIVER LABORATORIES, INC.
• EUROFINS SCIENTIFIC Ltd.
• SMITHERS
• SGS SA
• JRF GLOBAL
• MéRIEUX NUTRISCIENCES
• ALPHA ANALYTICAL INC.